NASDAQ · ANAB
Healthcare · Biotechnology
$51.00
Down-$0.70 (-1.35%)
Updated Sep 27, 2026, 5:26 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
ANAB closed at $51.00 after 19 trading sessions, down 10.57% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $52.38 | $52.38 | $50.7975 | $51.00 | 437.68K |
| Sep 24, 2026 | $50.59 | $52.16 | $50.35 | $51.70 | 418.4K |
| Sep 23, 2026 | $53.55 | $53.9275 | $49.4501 | $50.77 | 779.61K |
| Sep 22, 2026 | $55.07 | $56.04 | $50.61 | $53.92 | 755.77K |
| Sep 21, 2026 | $56.00 | $56.00 | $54.09 | $54.92 | 525.05K |
| Sep 18, 2026 | $55.76 | $55.77 | $53.71 | $55.20 | 868.85K |
| Sep 17, 2026 | $55.09 | $55.79 | $54.49 | $55.06 | 439.57K |
| Sep 16, 2026 | $54.44 | $54.80 | $53.6228 | $54.31 | 394.07K |
| Sep 15, 2026 | $54.28 | $55.32 | $53.22 | $54.68 | 351.77K |
| Sep 14, 2026 | $54.58 | $55.70 | $54.00 | $54.11 | 436.88K |
| Sep 11, 2026 | $55.43 | $56.315 | $53.75 | $53.87 | 336.19K |
| Sep 10, 2026 | $55.43 | $56.43 | $54.31 | $55.16 | 300.15K |
| Sep 9, 2026 | $55.59 | $57.89 | $55.25 | $55.70 | 295.68K |
| Sep 8, 2026 | $55.48 | $58.165 | $54.79 | $56.60 | 1.04M |
| Sep 4, 2026 | $56.84 | $58.77 | $56.10 | $56.80 | 1.06M |
| Sep 3, 2026 | $56.33 | $57.77 | $55.00 | $57.46 | 366.85K |
| Sep 2, 2026 | $56.13 | $57.90 | $54.66 | $55.84 | 421.73K |
| Sep 1, 2026 | $56.82 | $58.09 | $54.84 | $55.28 | 773.86K |
| Aug 31, 2026 | $55.83 | $57.22 | $55.00 | $57.03 | 332.17K |
The latest Smart Investors Daily articles mentioning ANAB.
ANAB research
Company profile and research snapshot.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 23, 2026 | Leerink Partners | Outperform | — |
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 24, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | UBS | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 21, 2026
AnaptysBio (ANAB) delivered earnings and revenue surprises of +76.09% and +3.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Sep 21, 2026
Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growthPositive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA action date of February 2027 with eligibility for expedited review through the National Priority Voucher program, which could result in an earlier FDA decisionLitigation with GSK and Tesaro: trial held
Benzinga · Sep 21, 2026
AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.46) by 76.09 percent. This is a 91.79 percent increase over losses of $(1.34) per share from the
Yahoo · Sep 9, 2026
Alphyn Capital Management, an investment management firm, released its second-quarter 2026 investor letter. The letter can be downloaded here. The fund’s Master Account returned 0.6% net in the quarter compared to 15.2% for the S&P500. As of June 30, 2026, the top ten positions comprised approximately 72% of the portfolio, and the portfolio held approximately […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANAB.
